Today is shaping up negative for bluebird bio, Inc. (NASDAQ:BLUE) shareholders, with the analysts delivering a substantial negative revision to next year's forecasts. There was a fairly draconian cut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback